Abraxis BioScience, Inc. Reports Record Revenue of $765 Million in 2006 Versus $521 Million for 2005

February 26, 2007 |

1 min read

LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today reported financial results for the full year and fourth quarter ended December 31, 2006.

Earnings

MORE ON THIS TOPIC

Podcast

CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP

July 2, 2025

·

1 min read

·

Heather McKenzie

A contemporary artistic collage depicting a hand holding pills, passing them to another hand. The concept of medication and treatment.

Collaboration

Argenx Makes $1.5B+ Play for UNP’s Macrocyclic Peptides Aimed at ‘Undruggable’ Targets

July 1, 2025

·

2 min read

·

Tristan Manalac

Contemporary art collage, female palms in the orange circle, a bag of money. Concept of business and finance.

Mergers & acquisitions

AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies

June 30, 2025

·

2 min read

·

Dan Samorodnitsky

Illustration showing businessman bringing personal items in box stock

Layoffs

BMS Continues New Jersey Layoffs, Bringing Yearly Total to Nearly 900

June 30, 2025

·

1 min read

·